Asciminib In Second-Line CML Treatment

  • The ASC2ESCALATE Phase 2 trial evaluated asciminib in second-line CML using a two-step adaptive dose escalation protocol—beginning with the FDA-approved 80mg dose, then adjusting at Weeks 24 and 48 based on molecular response.
  • In second-line treatment of chronic-phase chronic myeloid leukemia (CML-CP), asciminib showed strong molecular response rates at Week 24. Asciminib was well tolerated, and the findings support asciminib’s viability as an option in the second-line CML-CP setting.
  • At Week 24, 82.5% of patients stayed on the standard dose with BCR-ABL PCR <1%, and 44.4% achieved major molecular response (MMR), suggesting promising tolerability and efficacy in early treatment windows.
  • Asciminib targets the ABL Myristoyl pocket—unlike ATP-binding TKIs—potentially bypassing resistance mutations like T315I and contributing to a unique, low-toxicity profile.
  • Dr. David J. Andorsky of the Rocky Mountain Cancer Center and Sarah Cannon Research Institute, and an investigator for the ASC2ESCALATE trial, says asciminib’s tendency to target the ABL Myristoyl pocket, “may explain its side effect profile being a little bit different.”
  • Asciminib’s flexible dosing and tolerability underscore the need for frequent PCR monitoring, careful patient selection, and proactive education—positioning it as a strong contender for second-line and potentially frontline use.

Dr. David J. Andorsky of the Rocky Mountain Cancer Center and Sarah Cannon Research Institute, and an investigator for the ASC2ESCALATE Phase 2 trial,  is studying the tolerability and response of asciminib in patients with chronic myeloid leukemia (CML) who previously received a TKI and are now receiving second-line therapy.

“This trial has a somewhat unique design,” said Dr. Andorsky, “in that it takes patients and starts them on the 80 milligram daily dose, which is the current FDA-approved dose. And then at 24 weeks and 48 weeks, patients are assessed for response.”

The trial employed a two-step escalation protocol:

  • At Week 24, patients with BCR-ABL PCR >1% were escalated from 80mg to 200mg daily.
  • At Week 48, another escalation opportunity was offered to patients who had not achieved a major molecular response (MMR).

Among the 63 patients evaluable at Week 24:

  • 82.5% had PCR <1% and remained on the standard dose.
  • 44.4% achieved MMR
  • 9.5% reached MR4 or deeper response

While the number of dose escalations was small, future analyses will examine whether those patients who experienced an escalation experience improved outcomes.

Unlike first-generation TKIs that competitively bind to the ATP pocket, asciminib is distinguished by its targeting of the ABL Myristoyl pocket—offering a novel mechanism that may sidestep common resistance mutations.

“This may explain its side effect profile being a little bit different,” Andorsky suggested. He emphasized asciminib’s efficacy against the T315I mutation, which confers resistance to four of the five other approved TKIs.

Common side effects for asciminib may include: muscle, bone, or joint pain, diarrhea, stomach pain, and nose, throat, or sinus infections.

For oncologists managing CML patients who have failed first-line therapy, asciminib offers:

  • A well-tolerated alternative with low-grade toxicity
  • An adaptive dosing option responsive to molecular monitoring
  • A mechanistic advantage for mutation-resistant disease

With increased data, especially regarding dose escalation outcomes, asciminib could solidify its role not only in second-line treatment but also challenge existing practices in frontline settings.

Researchers conclude that in second-line treatment of chronic-phase chronic myeloid leukemia (CML-CP), asciminib showed strong molecular response rates at Week 24, aligning with its established safety profile across treatment lines. No new or exacerbated safety signals were observed during this interim analysis. The drug was well tolerated, with minimal adverse events leading to discontinuation. These findings support asciminib’s viability as a therapeutic option in the second-line CML-CP setting.

What It Means for Practice

Physicians may need to incorporate structured PCR testing timelines to assess eligibility for dose escalation.

  • Patient Selection: Ideal candidates are those with poor tolerance or resistance to ATP-binding TKIs.
  • Education & Communication: Physicians should proactively counsel patients on the trial’s rationale and emphasize asciminib’s tolerability profile to support adherence.